Low Phillip A, Benrud-Larson Lisa M, Sletten David M, Opfer-Gehrking Tonette L, Weigand Stephen D, O'Brien Peter C, Suarez Guillermo A, Dyck Peter J
Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Diabetes Care. 2004 Dec;27(12):2942-7. doi: 10.2337/diacare.27.12.2942.
The prevalence of autonomic symptoms and deficits in certain systems is known, but a comprehensive autonomic symptom profile in diabetes is not available. We aimed to estimate this using a laboratory evaluation of autonomic function and a validated self-report measure of autonomic symptoms in patients and matched control subjects from the population-based Rochester Diabetic Neuropathy Study.
Participants included 231 patients with diabetes (type 1, n=83; type 2, n=148) and 245 healthy age-matched control subjects. We assessed symptoms using a validated self-report instrument (Autonomic Symptom Profile) and evaluated the severity and distribution of autonomic deficits (cardiovagal, sudomotor, adrenergic) with the objective, laboratory-based Composite Autonomic Severity Score (CASS).
Autonomic symptoms were present more commonly in type 1 than in type 2 diabetes, with symptoms of orthostatic intolerance, secretomotor, urinary control, diarrhea, and sleep disturbance and pupillomotor, vasomotor, and erectile dysfunction significantly increased over healthy control subjects in type 2 diabetic patients. The prevalence of autonomic impairment was 54% in type 1 and 73% in type 2 diabetic patients. Severity of autonomic failure was mild overall (mean CASS 2.3; maximum 10), with orthostatic hypotension occurring in 8.4 and 7.4% of type 1 and 2 diabetic patients, respectively. Fourteen percent of patients had a CASS > or =5, indicating moderate to severe generalized autonomic failure. The correlation of symptoms with autonomic deficits (CASS) was better in type 1 than type 2 diabetic subjects and was weak overall.
These findings indicate that autonomic symptoms and deficits are common in diabetes, but mild in severity, and that the correlation between symptom scores and deficits is overall weak in mild diabetic neuropathy, emphasizing the need to separately evaluate autonomic symptoms.
已知某些系统中自主神经症状和功能障碍的患病率,但目前尚无糖尿病患者全面的自主神经症状概况。我们旨在通过对基于人群的罗切斯特糖尿病神经病变研究中的患者及匹配的对照受试者进行自主神经功能的实验室评估和经过验证的自主神经症状自我报告测量来对此进行评估。
参与者包括231例糖尿病患者(1型,n = 83;2型,n = 148)和245名年龄匹配的健康对照受试者。我们使用经过验证的自我报告工具(自主神经症状概况)评估症状,并通过基于实验室的客观综合自主神经严重程度评分(CASS)评估自主神经功能障碍(心血管迷走神经、汗腺运动神经、肾上腺素能神经)的严重程度和分布情况。
1型糖尿病患者中自主神经症状比2型糖尿病患者更常见,2型糖尿病患者中体位性不耐受、分泌运动、排尿控制、腹泻和睡眠障碍以及瞳孔运动、血管运动和勃起功能障碍的症状比健康对照受试者显著增加。1型糖尿病患者自主神经功能损害的患病率为54%,2型糖尿病患者为73%。自主神经功能衰竭总体严重程度较轻(平均CASS为2.3;最高为10),1型和2型糖尿病患者分别有8.4%和7.4%发生体位性低血压。14%的患者CASS≥5,表明存在中度至重度广泛性自主神经功能衰竭。1型糖尿病受试者中症状与自主神经功能障碍(CASS)的相关性比2型糖尿病受试者更好,且总体相关性较弱。
这些发现表明自主神经症状和功能障碍在糖尿病中很常见,但严重程度较轻,且在轻度糖尿病神经病变中症状评分与功能障碍之间的相关性总体较弱,强调了需要单独评估自主神经症状。